Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Cough up an update soon
View:
Post by Joemare on Nov 04, 2022 10:13am

Cough up an update soon

Either they are capable of recruting or not. I think that it's time for the elites at THERA cough up their know-how. They can't hide much longer.  
a) Clinical trial update, accrual, clearer timelines for data release

Quite simple.  Do they have the know-how to sell the clinical trials to investigators and have investigators sell the concept of TH1902 to patients. Not easy for a patient to accept going back to docetaxel when it failed them.  That's where THERA's leadership comes into play.
Comment by Biobob on Nov 04, 2022 10:23am
It is running long in the tooth.  Paul's comment on lazer focussing recruitment did highlight somekind of impatience on his behalf.  So it's longer than hoped from where I stand.  The fact that some disgruntled shareholders came out almost happy from their private meeting from what we eard gives me hope at least.  Longer does'nt mean that it aint working tough.  ...more  
Comment by Joemare on Nov 04, 2022 10:33am
Yesterday's trading was indeed intriguing.  At this point, it's not even POC or P1 results.  It's about the konw-how to conduct phase I trial and leadership to recruit patients via their ability to sell the idea to principal investigators of their  'key to cancer' technology. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities